InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Yuan Qing Sarah. Director active across 1 company, notably Sigilon Therapeutics, Inc.. Cumulatively, 2 disclosures have been logged. History available since 27 July 2023. The latest transaction was filed on 27 July 2023 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
2 of 2 declarations